CTLA-4/CD80/CD86—hampering T cell immunity against hematological malignancies (83) and modulating immune responses in AML (90).Blocking of CTLA-4 pathway—increase of anti-leukemia T-cell immune response translated in prolonged tumor regression (91, 92). Here, CD80 is linked to leukemia.